{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:07Z","timestamp":1791906427058,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Liaoning Province science and technology plan project","award":["2024011335-JH2\/1026"],"award-info":[{"award-number":["2024011335-JH2\/1026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02249-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:06:00Z","timestamp":1784300760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on the regulation of mesothelioma driven by deubiquitinating enzyme BAP1"],"prefix":"10.1007","volume":"26","author":[{"given":"Wan-Ting","family":"Xuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Na","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Xi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"9","key":"2249_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.6004\/jnccn.2023.0045","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Stevenson J, Ettinger DS, Wood DE, Stevenson J, et al. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Cancer Network: JNCCN. 2023;21(9):961\u201379.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"6","key":"2249_CR2","first-page":"1433","volume":"29","author":"I Ahmed","year":"2013","unstructured":"Ahmed I, Tipu SA, Ishtiaq S. Malignant mesothelioma [J]. Pakistan J Med Sci. 2013;29(6):1433.","journal-title":"Pakistan J Med Sci"},{"issue":"4","key":"2249_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jtcvs.2020.02.141","volume":"160","author":"DT Severson","year":"2020","unstructured":"Severson DT, De Rienzo A, Bueno R. Mesothelioma in the age of Omics: Before and after The Cancer Genome Atlas [J]. J Thorac Cardiovasc Surg. 2020;160(4):1078\u2013e832.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"2249_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/jcb.25095","volume":"116","author":"J Dragon","year":"2015","unstructured":"Dragon J, Thompson J, MacPherson M, et al. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure [J]. J Cell Biochem. 2015;116(8):1540\u201352.","journal-title":"J Cell Biochem"},{"issue":"5","key":"2249_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification [J]. J Thorac oncology: official publication Int Association Study Lung Cancer. 2022;17(5):608\u201322.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"2249_CR6","doi-asserted-by":"crossref","unstructured":"Dacic S. Pleural mesothelioma classification-update and challenges [J]. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 2022, 35(Suppl 1): 51\u2009\u2013\u20096.","DOI":"10.1038\/s41379-021-00895-7"},{"key":"2249_CR7","doi-asserted-by":"crossref","unstructured":"Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma [J]. Eur respiratory review: official J Eur Respiratory Soc, 2021, 30(159).","DOI":"10.1183\/16000617.0226-2020"},{"issue":"1","key":"2249_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/JS9.0000000000001900","volume":"111","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li J, Tan F, et al. Assessing the global burden of mesothelioma: trends, socioeconomic influences, and asbestos exposure - a retrospective cohort study [J]. Int J Surg (London England). 2025;111(1):93\u2013103.","journal-title":"Int J Surg (London England)"},{"issue":"3","key":"2249_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.mrrev.2007.08.001","volume":"658","author":"D Ugolini","year":"2008","unstructured":"Ugolini D, Neri M, Ceppi M, et al. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor [J]. Mutat Res. 2008;658(3):162\u201371.","journal-title":"Mutat Res"},{"issue":"9270","key":"2249_CR10","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/S0140-6736(00)04922-9","volume":"357","author":"V Ascoli","year":"2001","unstructured":"Ascoli V, Mecucci C, Knuutila S. Genetic susceptibility and familial malignant mesothelioma [J]. Lancet (London England). 2001;357(9270):1804.","journal-title":"Lancet (London England)"},{"issue":"1","key":"2249_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses [J]. J Cell Physiol. 2012;227(1):44\u201358.","journal-title":"J Cell Physiol"},{"key":"2249_CR12","doi-asserted-by":"publisher","first-page":"115085","DOI":"10.1016\/j.envres.2022.115085","volume":"230","author":"Y Gao","year":"2023","unstructured":"Gao Y, Mazurek JM, Li Y, et al. Industry, occupation, and exposure history of mesothelioma patients in the U.S. National Mesothelioma Virtual Bank, 2006\u20132022 [J]. Environ Res. 2023;230:115085.","journal-title":"Environ Res"},{"issue":"5","key":"2249_CR13","first-page":"979","volume":"134","author":"Y Ke","year":"1989","unstructured":"Ke Y, Reddel RR, Gerwin BI, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma [J]. Am J Pathol. 1989;134(5):979\u201391.","journal-title":"Am J Pathol"},{"key":"2249_CR14","doi-asserted-by":"crossref","unstructured":"Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40 [J]. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY), 1960, 105: 420-7.","DOI":"10.3181\/00379727-105-26128"},{"key":"2249_CR15","unstructured":"\u59da\u5a1c\u5a1c. \u95f4\u76ae\u7624\u4e2d\u733f\u7334\u75c5\u6bd2SV40\u7684\u8868\u8fbe\u4e0e\u81f4\u75c5\u6027\u7684\u7814\u7a76 [D]; \u4e2d\u56fd\u533b\u79d1\u5927\u5b66, 2025."},{"key":"2249_CR16","doi-asserted-by":"publisher","first-page":"660039","DOI":"10.3389\/fonc.2021.660039","volume":"11","author":"S Hiltbrunner","year":"2021","unstructured":"Hiltbrunner S, Mannarino L, Kirschner MB, et al. Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma [J]. Front Oncol. 2021;11:660039.","journal-title":"Front Oncol"},{"issue":"2","key":"2249_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbagen.2016.09.031","volume":"1861","author":"T Padmore","year":"2017","unstructured":"Padmore T, Stark C, Turkevich LA, et al. Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages [J]. Biochim et Biophys acta Gen Subj. 2017;1861(2):58\u201367.","journal-title":"Biochim et Biophys acta Gen Subj"},{"issue":"12","key":"2249_CR18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma [J]. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"key":"2249_CR19","first-page":"100232","volume":"25","author":"P Markowitz","year":"2020","unstructured":"Markowitz P, Patel M, Groisberg R, et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes [J]. Cancer Treat Res Commun. 2020;25:100232.","journal-title":"Cancer Treat Res Commun"},{"key":"2249_CR20","doi-asserted-by":"crossref","unstructured":"Pirker C, Bilecz A, Grusch M, et al. Clin cancer research: official J Am Association Cancer Res. 2020;26(14):3819\u201330. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup [J].","DOI":"10.1158\/1078-0432.CCR-19-3573"},{"key":"2249_CR21","doi-asserted-by":"crossref","unstructured":"Dacic S, Roy S, Lyons MA et al. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ [J]. Lung cancer (Amsterdam, Netherlands), 2020, 149: 1\u20134.","DOI":"10.1016\/j.lungcan.2020.09.002"},{"issue":"10","key":"2249_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","volume":"35","author":"DB Chapel","year":"2022","unstructured":"Chapel DB, Hornick JL, Barlow J, et al. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma [J]. Mod pathology: official J United States Can Acad Pathol Inc. 2022;35(10):1383\u201397.","journal-title":"Mod pathology: official J United States Can Acad Pathol Inc"},{"issue":"8","key":"2249_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone M, Harbour JW, Brugarolas J, et al. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer [J]. Cancer Discov. 2020;10(8):1103\u201320.","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"2249_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","volume":"9","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Husain AN, et al. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma [J]. Translational lung cancer Res. 2020;9(Suppl 1):S3\u201327.","journal-title":"Translational lung cancer Res"},{"issue":"12","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s11912-023-01479-1","volume":"25","author":"A Nash","year":"2023","unstructured":"Nash A, Creaney J. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths [J]. Curr Oncol Rep. 2023;25(12):1515\u201322.","journal-title":"Curr Oncol Rep"},{"key":"2249_CR26","doi-asserted-by":"crossref","unstructured":"Elsayed AM, Kittaneh M, Cebulla CM et al. An overview of BAP1 biological functions and current therapeutics [J]. Biochimica et biophysica acta Reviews on cancer, 2025, 1880(2): 189267.","DOI":"10.1016\/j.bbcan.2025.189267"},{"key":"2249_CR27","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein [J]. Cancer Treat Rev. 2020;90:102091.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2249_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/path.5551","volume":"253","author":"A De Rienzo","year":"2021","unstructured":"De Rienzo A, Chirieac LR, Hung YP, et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma [J]. J Pathol. 2021;253(1):68\u201379.","journal-title":"J Pathol"},{"key":"2249_CR29","doi-asserted-by":"crossref","unstructured":"Panou V, R\u00f8e OD. Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review [J]. Int J Mol Sci, 2020, 21(12).","DOI":"10.3390\/ijms21124327"},{"key":"2249_CR30","doi-asserted-by":"publisher","first-page":"1353138","DOI":"10.3389\/fimmu.2024.1353138","volume":"15","author":"Y Liang","year":"2024","unstructured":"Liang Y, Wang H, Seija N, et al. B-cell intrinsic regulation of antibody mediated immunity by histone H2A deubiquitinase BAP1 [J]. Front Immunol. 2024;15:1353138.","journal-title":"Front Immunol"},{"key":"2249_CR31","doi-asserted-by":"publisher","first-page":"626418","DOI":"10.3389\/fimmu.2021.626418","volume":"12","author":"YH Lin","year":"2021","unstructured":"Lin YH, Liang Y, Wang H, et al. Regulation of B Lymphocyte Development by Histone H2A Deubiquitinase BAP1 [J]. Front Immunol. 2021;12:626418.","journal-title":"Front Immunol"},{"issue":"4","key":"2249_CR32","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1073\/pnas.1908003117","volume":"117","author":"J Vohhodina","year":"2020","unstructured":"Vohhodina J, Toomire KJ, Petit SA, et al. RAP80 and BRCA1 PARsylation protect chromosome integrity by preventing retention of BRCA1-B\/C complexes in DNA repair foci [J]. Proc Natl Acad Sci USA. 2020;117(4):2084\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2249_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13059-022-02776-x","volume":"23","author":"N Tsuboyama","year":"2022","unstructured":"Tsuboyama N, Szczepanski AP, Zhao Z, et al. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer [J]. Genome Biol. 2022;23(1):206.","journal-title":"Genome Biol"},{"issue":"21","key":"2249_CR34","doi-asserted-by":"publisher","first-page":"12291","DOI":"10.1093\/nar\/gkac1153","volume":"50","author":"S Trivedi","year":"2022","unstructured":"Trivedi S, Blaz\u00edckov\u00e1 J, Silva N. PARG and BRCA1-BARD1 cooperative function regulates DNA repair pathway choice during gametogenesis [J]. Nucleic Acids Res. 2022;50(21):12291\u2013308.","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"2249_CR35","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","volume":"81","author":"E Conway","year":"2021","unstructured":"Conway E, Rossi F, Fernandez-Perez D, et al. BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation [J]. Mol Cell. 2021;81(17):3526\u2013e418.","journal-title":"Mol Cell"},{"issue":"7659","key":"2249_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi A, Giorgi C, Patergnani S, et al. BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation [J]. Nature. 2017;546(7659):549\u201353.","journal-title":"Nature"},{"key":"2249_CR37","doi-asserted-by":"crossref","unstructured":"Salut N, Gamallat Y, Seyedi S et al. Unraveling the Prognostic Significance of BRCA1-Associated Protein 1 (BAP1) Expression in Advanced and Castrate-Resistant Prostate Cancer [J]. Biology, 2025, 14(3).","DOI":"10.3390\/biology14030315"},{"issue":"2","key":"2249_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","volume":"28","author":"L Masclef","year":"2021","unstructured":"Masclef L, Ahmed O, Estavoyer B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression [J]. Cell Death Differ. 2021;28(2):606\u201325.","journal-title":"Cell Death Differ"},{"issue":"20","key":"2249_CR39","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1042\/BCJ20190622","volume":"476","author":"HS Lee","year":"2019","unstructured":"Lee HS, Seo HR, Lee SA, et al. BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress [J]. Biochem J. 2019;476(20):3053\u201366.","journal-title":"Biochem J"},{"issue":"7295","key":"2249_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC Scheuermann","year":"2010","unstructured":"Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB [J]. Nature. 2010;465(7295):243\u20137.","journal-title":"Nature"},{"issue":"1","key":"2249_CR41","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-020-19722-9","volume":"11","author":"H Barbour","year":"2020","unstructured":"Barbour H, Daou S, Hendzel M, et al. Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes [J]. Nat Commun. 2020;11(1):5947.","journal-title":"Nat Commun"},{"key":"2249_CR42","doi-asserted-by":"crossref","unstructured":"Bonacci T, Emanuele MJ. Dissenting degradation: Deubiquitinases in cell cycle and cancer [J]. Seminars in cancer biology, 2020, 67(Pt 2): 145\u2009\u2013\u200958.","DOI":"10.1016\/j.semcancer.2020.03.008"},{"issue":"11","key":"2249_CR43","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/0008-5472.CAN-20-3430","volume":"81","author":"A Han","year":"2021","unstructured":"Han A, Purwin TJ, Aplin AE. Roles of the BAP1 Tumor Suppressor in Cell Metabolism [J]. Cancer Res. 2021;81(11):2807\u201314.","journal-title":"Cancer Res"},{"issue":"2","key":"2249_CR44","first-page":"29","volume":"5","author":"NAE-G Heabah","year":"2021","unstructured":"Heabah NAE-G, Eid AM. Comparative study of BAP1 and CD147 expression in the diagnosis of malignant mesothelioma [J]. Egypt J Cancer Biomedical Res. 2021;5(2):29\u201337.","journal-title":"Egypt J Cancer Biomedical Res"},{"key":"2249_CR45","doi-asserted-by":"crossref","unstructured":"Hong AW, Meng Z, Plouffe SW et al. Critical roles of phosphoinositides and NF2 in Hippo pathway regulation [J]. Genes & development, 2020, 34(7\u20138): 511\u2009\u2013\u200925.","DOI":"10.1101\/gad.333435.119"},{"issue":"2","key":"2249_CR46","doi-asserted-by":"publisher","first-page":"e1190","DOI":"10.1002\/ctm2.1190","volume":"13","author":"R Cunningham","year":"2023","unstructured":"Cunningham R, Jia S, Purohit K, et al. YAP\/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations [J]. Clin translational Med. 2023;13(2):e1190.","journal-title":"Clin translational Med"},{"issue":"8","key":"2249_CR47","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/0008-5472.CAN-19-1704","volume":"80","author":"H-J Lee","year":"2020","unstructured":"Lee H-J, Pham T, Chang MT, et al. The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma [J]. Cancer Res. 2020;80(8):1656\u201368.","journal-title":"Cancer Res"},{"issue":"5","key":"2249_CR48","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.modpat.2025.100706","volume":"38","author":"RE Fanaroff","year":"2025","unstructured":"Fanaroff RE, Yang SR, Tan KS, et al. Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma [J]. Mod pathology: official J United States Can Acad Pathol Inc. 2025;38(5):100706.","journal-title":"Mod pathology: official J United States Can Acad Pathol Inc"},{"key":"2249_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-pathol-042420-092719","volume":"19","author":"CA Febres-Aldana","year":"2024","unstructured":"Febres-Aldana CA, Fanaroff R, Offin M, et al. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment [J]. Annu Rev Pathol. 2024;19:11\u201342.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2249_CR50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1186\/s12967-023-04614-5","volume":"21","author":"M Carbone","year":"2023","unstructured":"Carbone M, Minaai M, Takinishi Y, et al. Preventive and therapeutic opportunities: targeting BAP1 and\/or HMGB1 pathways to diminish the burden of mesothelioma [J]. J translational Med. 2023;21(1):749.","journal-title":"J translational Med"},{"issue":"4","key":"2249_CR51","doi-asserted-by":"publisher","first-page":"e2217840120","DOI":"10.1073\/pnas.2217840120","volume":"120","author":"A Bononi","year":"2023","unstructured":"Bononi A, Wang Q, Zolondick AA, et al. BAP1 is a novel regulator of HIF-1\u03b1 [J]. Proc Natl Acad Sci USA. 2023;120(4):e2217840120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2249_CR52","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","volume":"79","author":"AM Kukuyan","year":"2019","unstructured":"Kukuyan AM, Sementino E, Kadariya Y, et al. Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models [J]. Cancer Res. 2019;79(16):4113\u201323.","journal-title":"Cancer Res"},{"issue":"1","key":"2249_CR53","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Luo JL, Sun Q, et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment [J]. Nat Commun. 2021;12(1):1751.","journal-title":"Nat Commun"},{"issue":"7","key":"2249_CR54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma [J]. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"8","key":"2249_CR55","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2013.130","volume":"108","author":"R Mezzapelle","year":"2013","unstructured":"Mezzapelle R, Miglio U, Rena O, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma [J]. Br J Cancer. 2013;108(8):1743\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"2249_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","volume":"86","author":"T Shukuya","year":"2014","unstructured":"Shukuya T, Serizawa M, Watanabe M, et al. Identification of actionable mutations in malignant pleural mesothelioma [J]. Lung cancer (Amsterdam Netherlands). 2014;86(1):35\u201340.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"3","key":"2249_CR57","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","volume":"10","author":"M Lo Iacono","year":"2015","unstructured":"Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study [J]. J Thorac oncology: official publication Int Association Study Lung Cancer. 2015;10(3):492\u20139.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"issue":"2","key":"2249_CR58","doi-asserted-by":"publisher","first-page":"e13631","DOI":"10.15252\/emmm.202013631","volume":"14","author":"A Marazioti","year":"2022","unstructured":"Marazioti A, Krontira AC, Behrend SJ, et al. KRAS signaling in malignant pleural mesothelioma [J]. EMBO Mol Med. 2022;14(2):e13631.","journal-title":"EMBO Mol Med"},{"key":"2249_CR59","doi-asserted-by":"crossref","unstructured":"Kato T, Tanaka I, Huang H et al. Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma [J]. Int J Mol Sci, 2025, 26(9).","DOI":"10.3390\/ijms26094299"},{"issue":"11","key":"2249_CR60","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/s41416-024-02661-3","volume":"130","author":"N Landman","year":"2024","unstructured":"Landman N, Hulsman D, Badhai J, et al. Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma [J]. Br J Cancer. 2024;130(11):1855\u201365.","journal-title":"Br J Cancer"},{"key":"2249_CR61","doi-asserted-by":"publisher","first-page":"e2400845","DOI":"10.1200\/PO-24-00845","volume":"9","author":"EC West","year":"2025","unstructured":"West EC, Evangelista J, Campanella A, et al. BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma [J]. JCO precision Oncol. 2025;9:e2400845.","journal-title":"JCO precision Oncol"},{"key":"2249_CR62","doi-asserted-by":"crossref","unstructured":"Hakim SA, Abou Gabal HH. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study [J]. Volume 27. Pathology oncology research: POR,; 2021. p. 600073.","DOI":"10.3389\/pore.2021.600073"},{"issue":"5","key":"2249_CR63","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","volume":"103","author":"Y Yoshikawa","year":"2012","unstructured":"Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma [J]. Cancer Sci. 2012;103(5):868\u201374.","journal-title":"Cancer Sci"},{"issue":"9","key":"2249_CR64","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/cas.12722","volume":"106","author":"T Mori","year":"2015","unstructured":"Mori T, Sumii M, Fujishima F, et al. Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma [J]. Cancer Sci. 2015;106(9):1118\u201329.","journal-title":"Cancer Sci"},{"issue":"6","key":"2249_CR65","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","volume":"23","author":"MG Zauderer","year":"2022","unstructured":"Zauderer MG, Szlosarek PW, Le Moulec S, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study [J]. Lancet Oncol. 2022;23(6):758\u201367.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2249_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2767-9764.CRC-23-0276","volume":"4","author":"J Badhai","year":"2024","unstructured":"Badhai J, Landman N, Pandey GK, et al. Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma [J]. Cancer Res Commun. 2024;4(1):18\u201327.","journal-title":"Cancer Res Commun"},{"issue":"2","key":"2249_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1541-7786.MCR-20-0434","volume":"19","author":"JN Kuznetsoff","year":"2021","unstructured":"Kuznetsoff JN, Owens DA, Lopez A, et al. Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma [J]. Mol cancer research: MCR. 2021;19(2):215\u201322.","journal-title":"Mol cancer research: MCR"},{"key":"2249_CR68","doi-asserted-by":"publisher","first-page":"e2400406","DOI":"10.1200\/PO-24-00406","volume":"8","author":"TJ George","year":"2024","unstructured":"George TJ, Lee JH, DeRemer DL, et al. Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms [J]. JCO precision Oncol. 2024;8:e2400406.","journal-title":"JCO precision Oncol"},{"key":"2249_CR69","doi-asserted-by":"crossref","unstructured":"Ghafoor A, Mian I, Wagner C, et al. Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene [J]. Volume 2. JTO clinical and research reports; 2021. p. 100231. 10.","DOI":"10.1016\/j.jtocrr.2021.100231"},{"issue":"1","key":"2249_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12943-017-0587-x","volume":"16","author":"M Parasramka","year":"2017","unstructured":"Parasramka M, Yan IK, Wang X, et al. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma [J]. Mol Cancer. 2017;16(1):22.","journal-title":"Mol Cancer"},{"issue":"1","key":"2249_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","volume":"11","author":"M Ladanyi","year":"2019","unstructured":"Ladanyi M, Sanchez Vega F, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma [J]. Genome Med. 2019;11(1):18.","journal-title":"Genome Med"},{"issue":"6","key":"2249_CR72","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","volume":"9","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial [J]. Lancet Respiratory Med. 2021;9(6):593\u2013600.","journal-title":"Lancet Respiratory Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02249-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:07:12Z","timestamp":1791904032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02249-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"was obtained from the participants.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"351"}}